A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.

<h4>Background</h4>We set out a systemic review to evaluate whether off-label bevacizumab is as safe as licensed ranibizumab, and whether bevacizumab can be justifiably offered to patients as a treatment for age-related macular degeneration with robust evidence of no differential risk.&l...

Full description

Saved in:
Bibliographic Details
Main Authors: Christine Schmucker, Christoph Ehlken, Hansjuergen T Agostini, Gerd Antes, Gerta Ruecker, Monika Lelgemann, Yoon K Loke
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0042701&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items